Pharmacological treatments based on inhibition of this pathway have been developed and tested in mouse models for Fragile X syndrome [84], eIF4E dysregulation [85], and TSC1 and TSC2 [86, 87], with amelioration of autism-associated deficits in all cases. This evidence concerns the gene TSC2 and fragile X syndrome.